Order a test

Helping you make informed decisions and formulate effective treatment plans

More about RGCC

Information for patients

We work with your healthcare provider to deliver a range of personalised tests so you can choose the best treatment together.

More patient information
YouTube

By loading the video, you agree to YouTube's privacy policy.
Learn more

Load video

Stay tuned for RGCC's Cancer App Version 2.0 Coming Soon!

FAQs

Find answers to some of your most frequently asked questions

Medical Professionals

Do I need to sign any paperwork?In which countries are RGCC tests approved for use?How many types of cancer are tested when RGCC says “all types of cancer”?Can RGCC test for BRAF drugs?

Patient Information

How long do test results take to process?Are your testing methods accredited internationally?

Cancer Tests

New methods and reliable tests to help deliver personalised treatment

Onco-D-Clare

Onco-D-Clare is a cancer screening test based on the interaction of molecular biology with artificial neural networks. This screening test can help detect cancer before symptoms appear. Peripheral blood mononuclear cells are isolated from blood samples, and gene expression analysis is performed in more than 90 genes. Their expression profile is then used for the […]

View test

InVyomma Plus

InVyomma Plus focuses on gut microbiome profiling, including analysis of short-chain fatty acids, and how they are associated with cancer. It has been discovered that the microbiome is closely related to the occurrence and development of a variety of cancer types in the epithelial barrier and sterile tissues. Symbiotic ecosystems that inhabit the gut or […]

View test

Onconomics Extracts+

Onconomics Extracts+ provides highly detailed and accurate information about how effective specific natural substances and plant extracts are, as anticancer agents as well as the gene expression profile of genes, associated with fundamental biological processes. This includes processes such as angiogenesis, cell cycle regulation, self-repair, metastasis, apoptosis, proliferation etc. Circulating tumor cells are isolated from […]

View test

RGCC CAMBISeq®

RGCC CAMBISeq® is an innovative test that uses next-generation sequencing analysis on both DNA and RNA to provide clinicians with crucial insight into cancer.

View test

Array comparative genomic hybridisation (aCGH) RGCC

The array comparative genomic hybridisation (aCGH) RGCC test is used to identify chromosomal abnormalities in a patient that could lead to cancer.

View test

Immune-Frame

Immune-Frame is used to assess the condition of a patient’s immune system. Scientists use the test to identify specific cellular markers that are responsible for switching a patient’s immune system on and off.

View test

Metastat RGCC

Metastat RGCC is an advanced test to detect specific blood-borne markers that can accurately determine whether a secondary cancerous tumour is likely to develop and its potential location.

View test

ChemoSNiP

ChemoSNiP is an innovative test that uses an advanced scientific technique called pharmacogenomics to analyse how a patient’s body will respond to a specific drug.

View test

Onconomics Extracts

Onconomics Extracts is a unique and highly detailed test that provides information on how effective natural substances and plants extracts are at attacking circulating cancer cells (CTCs).

View test

Onconomics Plus RGCC

Onconomics Plus RGCC provides information about the effect of specific anti-cancer drugs, targeted therapies and natural treatments on the cancer cells in an individual patient.

View test

Onconomics RGCC

Onconomics RGCC provides highly detailed and accurate information about how effective specific anti-cancer drugs and targeted therapies are in treating cancer.

View test

Oncotrail RGCC

Oncotrail RGCC provides crucial information on the presence of circulating tumour cells (CTCs) and their concentration in patients who have a confirmed diagnosis of specific forms of cancer, including breast, colon and prostate cancer.

View test
See all RGCC tests

Use our ‘smart filter’ to identify which test is best for your patients

Find out more

News & Events

Find out more about our latest research, trials and education days.

13th Day of Life Sciences

9th June 2022
ZHAW Life Sciences and Facility Management, Grüentalstrasse 14, 8820 Wädenswil(PDF 3,0 MB)

We are delighted to be one of the main sponsors at the 13th Day of Life Sciences on 9th June 2022. Register for the symposium ‘Competencies in Drug Discovery’ by 7th June, we look forward to seeing you there! Day of Life Sciences | ZHAW Life Sciences and Facility Management

Read more

Genetic mutation could hold the key to new breast cancer treatments

Posted: 3rd May 2022
Categories: Industry news

Scientists have identified a mutated gene that causes breast cancer to become more aggressive and spread to other parts of the body in up to 30% of patients. The discovery provides exciting new avenues to develop new treatments for breast cancer, including more effective personalised approaches. Hormone therapy effectively treats around two-thirds of breast cancers, […]

Read more

New immunotherapy target for colon cancer found

Posted: 8th April 2022
Categories: Industry news

German scientists have identified the proteins inside colon cancer cells that trick the immune system from seeing them as a threat. But, in lab tests, once researchers blocked the signals from the cells, the immune systems began to attack them. The insight could help scientists develop new and highly targeted immunotherapies for one of the […]

Read more

New tumour biobank powers personalised cancer treatments

Posted: 22nd March 2022
Categories: Industry news

Scientists have discovered new and more effective ways of growing breast cancer tumours that could accelerate research and the development of new treatments. Instead of transplanting human tumours into mice, they’ve developed a bank of “human patient-derived xenografts (PDXs)” that can be used to screen drugs. Used alongside personalised genetic tests could improve cancer treatment […]

Read more

SOTs effective at treating cancer in 77% of patients

Posted: 9th March 2022
Categories: RGCC news

Cancer patients treated with the highly targeted supportive oligonucleotide therapy (SOT) showed benefits in 77% of cases, RGCC scientists have found. A new paper published in the in vivo journal finds evidence that SOTs effectively target and kill cancer cells on their own or in tandem with other therapies.  Supportive oligonucleotide therapy is an advanced, […]

Read more
Google Maps

By loading the map, you agree to Google's privacy policy.
Learn more

Load map